Methodology Core This Core focuses on economic evaluation approaches, tools, and measures to support new and existing interdisciplinary research collaborations. Despite decades of research supporting a chronic disease approach to substance use disorder treatment and recovery, uptake and sustainment remain low. Some of the most important factors inhibiting adoption of evidence-based practices are concerns about the potential burden on staff and other resources, as well as overall budget impact. Changing current practices requires not only clinical evidence, but also consideration of additional costs and the reallocation of existing resources that will result from the changes. Economic analysis can directly address these issues by providing a detailed accounting of the costs to the provider of updating services, and more broadly inform ?real-world? resource allocation decisions by providing policymakers and payers with evidence on the net economic and health impact of new approaches and their fiscal viability over time. This requires considering both costs and consequences of a new intervention, often using a cost-effectiveness or cost-benefit analysis framework. The overall aim of CHERISH (Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV) is to develop and disseminate economic evidence that informs substance use disorder policy and HCV and HIV care of people who use substances. In this renewal period we will expand our focus to outcome and implementation research that is conducted at the individual, system, and community levels with the following specific aims: 1) to guide researchers in the design, implementation, and interpretation of economic analyses of treatment for substance use disorder, and HCV and HIV among people who use substances, and 2) to develop and apply methods that support economic evaluations for substance use disorder, and HCV and HIV among people who use substances with a focus on intervention implementation and adaptive interventions. Through the CHERISH Consultation Service and Research Affiliates Program, we will contribute to the development of new grant proposals with explicit economic aims, and will continue to connect with and advise qualifying researchers nationally to ensure that planned economic analyses are methodologically sound and feasible. We will expand the CHERISH Research Affiliates program so it can serve as a nationally-representative virtual community for researchers engaged in substance use disorder treatment health economic research. Working with existing studies and integrating data from third-party datasets and administrative records, we will develop analytic frameworks and tools for evaluating individual and systems-level substance use disorder and related implementation interventions. We will also develop economic evaluation methods for adaptive interventions. In collaboration with the Population Data & Modeling Core, we will assist researchers in using external data to enhance interpretation of economic evaluation results.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
2P30DA040500-06A1
Application #
10079947
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2025-04-30
Budget Start
2020-07-01
Budget End
2021-04-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Kapadia, Shashi N; Jeng, Philip J; Schackman, Bruce R et al. (2018) State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. Clin Infect Dis 66:1618-1620
Freiman, J Morgan; Jacobson, Karen R; Muyindike, Winnie R et al. (2018) Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 77:405-412
Friedmann, Peter D; Wilson, Donna; Nunes, Edward V et al. (2018) Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat 85:61-65
Kapadia, Shashi N; Wu, Chunyuan; Mayer, Kenneth H et al. (2018) No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS One 13:e0206577
McCollister, Kathryn E; Yang, Xuan; Murphy, Sean M et al. (2018) Criminal justice measures for economic data harmonization in substance use disorder research. Health Justice 6:17
Chen, Donna T; Ko, Tomohiro M; Allen, Ashleigh A et al. (2018) Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics 13:160-172
Graves, Rachel L; Andreyeva, Elena; Perrone, Jeanmarie et al. (2018) Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies. J Addict Med :
Liang, Di; Bao, Yuhua; Wallace, Mark et al. (2018) Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction 113:2060-2070
Graves, Rachel L; Tufts, Christopher; Meisel, Zachary F et al. (2018) Opioid Discussion in the Twittersphere. Subst Use Misuse 53:2132-2139
Schackman, Bruce R; Gutkind, Sarah; Morgan, Jake R et al. (2018) Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend 185:411-420

Showing the most recent 10 out of 93 publications